Trials containing IO agents other than PD-L1/PD-1 inhibitors without chemotherapy included agents targeting IL-10 inhibitor, toll-like receptor 9 (TLR9) agonist and cancer vaccines. This evidence concerns the gene TLR9 and cancer.